for Clinical Development of MaaT033 as part of the France 2030 Plan
Lyon, France, November 30, 2023 – 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, announced today that its ongoing Phase 2b trial, called Phoebus, aimed at evaluating MaaT033 to improve overall survival for patients receiving allo-HSCT2 has been selected for funding, in response to the ‘Innovation in Biotherapy and Bioproduction’ call for projects from the ‘Biotherapies and Bioproduction of Innovative Therapies’ acceleration strategy, operated by Bpifrance. (project called: METALLO[1]).
“We’re honored to receive this funding, contributing to France’s leadership in innovative biotherapies. This is consistent with announcements from the French government in accelerating production of biomedicines in France. We thank the Ministry of Industry for its support during the official opening of the new manufacturing facility constructed and operated in partnership with Skyepharma” commented Siân Crouzet, CFO of MaaT Pharma.
Read the press release